Rapid anti-myeloma activity by T cells expressing an anti-BCMA CAR with a human heavy-chain-only antigen-binding domain
Lekha Mikkilineni, James N. Kochenderfer(National Institutes of Health), Steven L. Highfill(National Institutes of Health), Constance M. Yuan(National Cancer Institute), Elisabet E. Manasanch(National Institutes of Health), Nathan Wong(Frederick National Laboratory for Cancer Research), Lipei Shao(National Institutes of Health Clinical Center), Tyler Lowe(National Institutes of Health), Kathryn R. Martin(University of Aberdeen), Jennifer N. Brudno(National Institutes of Health), Zhili Zheng(Unknown), Steven A. Rosenberg(National Cancer Institute), David F. Stroncek(Yale University), Norris Lam(National Institutes of Health), Jennifer Mann(National Institutes of Health), Stephanie L. Goff(Unknown), Ping Jin(Zhejiang Chinese Medical University), Rashmika Patel(National Institutes of Health), Danielle Natrakul(National Institutes of Health), Micaela Ganaden(National Institutes of Health), Hao‐Wei Wang(Fu Jen Catholic University), James C. Yang(National Taiwan University Hospital), Jared J. Gartner(National Institutes of Health), Irina Marić(Center for Cancer Research), Katherine A. Weissler(National Institutes of Health)
Cited by 16
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
miRDB: an online resource for microRNA target prediction and functional annotations
|Nucleic Acids Research|2014|1.9k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
|Journal of Clinical Oncology|2008|1.3k